FDA advisers uneasy about long-term bisphosphonate use.
Kate
K
Traynor
D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004348:Drug Labeling; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012308:Risk Management; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D050071:Bone Density Conservation Agents; D004164:Diphosphonates